Fig. 3
The adhesion ability and biocompatibility of MBCon and MBVEGFR2 in vitro. (A) Specific attachment of MBCon or MBVEGFR2 to human umbilical vein endothelial cells (HUVECs) with high expression of VEGFR2 was observed at inverted fluorescence microscopy. (B) Specific attachment of MBCon or MBVEGFR2 to human embryonic kidney cell line 293T with VEGFR2-nonexpression was observed at inverted fluorescence microscopy. (× 200; scale bar, 25 μm). (C) Quantification analysis of MBCon, MBVEGFR2 attachment to HUVECs and 293T respectively. (D) The cytocompatibility of different concentrations of MBCon and MBVEGFR2 on HUVECs was determined using CCK8 method. Hemolysis of red blood cells in the presence of MBCon(E) and MBVEGFR2(F) with various concentrations (n = 4). PBS and distilled water were used as negative and positive controls, respectively. (** P < 0.01, ns = nonsignificant)